-
公开(公告)号:US5721362A
公开(公告)日:1998-02-24
申请号:US715541
申请日:1996-09-18
申请人: Elias J. Corey , David Gin
发明人: Elias J. Corey , David Gin
IPC分类号: C07D317/60 , A61K31/4995 , A61P35/00 , C07D317/64 , C07D491/12 , C07D491/22 , C07D493/00 , C07D498/18 , C07D498/22 , C07D515/22
CPC分类号: C07D317/64
摘要: The present invention is directed to a synthetic process for the formation of ecteinascidin compounds and related structures, such as the saframycins. In one particularly preferred embodiment, the present invention provides a synthetic route for the formation of ecteinascidin 743 (1), ##STR1## an exceedingly potent and rare marine-derived antitumor agent which is slated for clinical trials. The process of this invention is enantio- and stereocontrolled, convergent and short. Also disclosed are novel process intermediates, useful not only in the total synthesis of ecteinascidin 743, but also other known ecteinascidin compounds, including derivatives and analogs thereof.
摘要翻译: 本发明涉及一种用于形成抗坏血酸素化合物和相关结构的合成方法,例如沙门菌素。 在一个特别优选的实施方案中,本发明提供了用于形成用于临床试验的非常有效和罕见的海洋衍生的抗肿瘤剂的抗坏血素素743(1)的合成途径。 本发明的方法是对称和立体控制的,收敛的和短的。 还公开了新的方法中间体,其不仅可用于全面合成海e素743,还可用于其它已知的海鞘类化合物,包括其衍生物和类似物。
-
公开(公告)号:US20130011421A1
公开(公告)日:2013-01-10
申请号:US13613312
申请日:2012-09-13
申请人: David Gin , Michelle Adams , Kai Deng , Nicholas Perl , Annie Won , Philip Livingston , Govind Ragupathi
发明人: David Gin , Michelle Adams , Kai Deng , Nicholas Perl , Annie Won , Philip Livingston , Govind Ragupathi
CPC分类号: C07H15/256 , A61K31/7024 , A61K31/704 , A61K39/385 , C07H13/08 , C07H15/24
摘要: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
摘要翻译: 本发明涉及三萜糖苷皂苷衍生的佐剂,其合成,其中间体及其用途。 QS-7是一种有效的免疫佐剂,其毒性明显低于QS-21,相关的皂苷是目前抗癌和抗病毒疫苗中有利的佐剂。 繁琐的分离和纯化方案阻碍了QS-7的临床发展。 提供了一种新的半合成方法,其中使用水解的前配皂素混合物合成QS-7,QS-21及相关类似物,极大地方便了QS-7和QS-21类似物的临床前和临床评估。
-
公开(公告)号:US08283456B2
公开(公告)日:2012-10-09
申请号:US12420803
申请日:2009-04-08
申请人: David Gin , Michelle Adams , Kai Deng , Nicholas Perl , Annie Won , Philip Livingston , Govind Ragupathi
发明人: David Gin , Michelle Adams , Kai Deng , Nicholas Perl , Annie Won , Philip Livingston , Govind Ragupathi
IPC分类号: C07H15/24
CPC分类号: C07H15/256 , A61K31/7024 , A61K31/704 , A61K39/385 , C07H13/08 , C07H15/24
摘要: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
摘要翻译: 本发明涉及三萜糖苷皂苷衍生的佐剂,其合成,其中间体及其用途。 QS-7是一种有效的免疫佐剂,其毒性明显低于QS-21,相关的皂苷是目前抗癌和抗病毒疫苗中有利的佐剂。 繁琐的分离和纯化方案阻碍了QS-7的临床发展。 提供了一种新的半合成方法,其中使用水解的前配皂素混合物合成QS-7,QS-21及相关类似物,极大地方便了QS-7和QS-21类似物的临床前和临床评估。
-
4.
公开(公告)号:US20110071097A1
公开(公告)日:2011-03-24
申请号:US12920227
申请日:2009-03-03
申请人: David Gin , Jeremy Wilmot , Hakim Djaballah
发明人: David Gin , Jeremy Wilmot , Hakim Djaballah
IPC分类号: A61K31/55 , C07D491/147 , C07H15/26 , A61K31/7052 , A61P35/00
CPC分类号: C07D491/147 , C07D491/14
摘要: The present invention provides novel cephalotaxus esters, syntheses thereof, and intermediates thereto. The invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of using said compounds or compositions in the treatment of proliferative diseases (e.g., benign neoplasm, cancer, inflammatory disease, autoimmune disease, diabetic retinopathy) and infectious disease. The invention further provides methods of using said compounds or compositions in the treatment of multidrug resistant cancer.
摘要翻译: 本发明提供新型头孢曲松酯,其合成物及其中间体。 本发明还提供包含本发明化合物和使用所述化合物或组合物治疗增殖性疾病(例如良性肿瘤,癌症,炎性疾病,自身免疫性疾病,糖尿病性视网膜病变)和感染性疾病的药物组合物。 本发明还提供了使用所述化合物或组合物治疗多重耐药性癌症的方法。
-
公开(公告)号:US08466142B2
公开(公告)日:2013-06-18
申请号:US12920227
申请日:2009-03-03
申请人: David Gin , Jeremy Wilmot , Hakim Djaballah
发明人: David Gin , Jeremy Wilmot , Hakim Djaballah
IPC分类号: A61K31/55 , C07D223/00 , C07D491/00
CPC分类号: C07D491/147 , C07D491/14
摘要: The present invention provides novel cephalotaxus esters, syntheses thereof, and intermediates thereto. The invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of using said compounds or compositions in the treatment of proliferative diseases (e.g., benign neoplasm, cancer, inflammatory disease, autoimmune disease, diabetic retinopathy) and infectious disease. The invention further provides methods of using said compounds or compositions in the treatment of multidrug resistant cancer.
-
公开(公告)号:US20110300177A1
公开(公告)日:2011-12-08
申请号:US12420803
申请日:2009-04-08
申请人: David Gin , Michelle Adams , Kai Deng , Nicholas Perl , Annie Won , Philip Livingston , Govind Ragupathi
发明人: David Gin , Michelle Adams , Kai Deng , Nicholas Perl , Annie Won , Philip Livingston , Govind Ragupathi
IPC分类号: A61K39/39 , A61K39/12 , A61K39/02 , A61P35/00 , A61K39/00 , A61P37/04 , A61P31/12 , A61P31/04 , C07H15/256 , A61K39/002
CPC分类号: C07H15/256 , A61K31/7024 , A61K31/704 , A61K39/385 , C07H13/08 , C07H15/24
摘要: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
摘要翻译: 本发明涉及三萜糖苷皂苷衍生的佐剂,其合成,其中间体及其用途。 QS-7是一种有效的免疫佐剂,其毒性明显低于QS-21,相关的皂苷是目前抗癌和抗病毒疫苗中有利的佐剂。 繁琐的分离和纯化方案阻碍了QS-7的临床发展。 提供了一种新的半合成方法,其中使用水解的前配皂素混合物合成QS-7,QS-21及相关类似物,极大地方便了QS-7和QS-21类似物的临床前和临床评估。
-
-
-
-
-